Michael R. Paterno

Efficacy and Safety of Besifloxacin Ophthalmic Suspension 0.6% Compared with Moxifloxacin Ophthalmic Solution 0.5% for Treating Bacterial Conjunctivitis

Marguerite B. McDonald, Eugene Protzko, Lynne S. Brunner et al. · Ophthalmology · 2009 · 80 citations

Ocular Disease, Ophthalmology, Eye Health +7

Phase III efficacy and safety study of besifloxacin ophthalmic suspension 0.6% in the treatment of bacterial conjunctivitis

Michael Tepedino, Warren Heller, Dale W. Usner et al. · Current Medical Research and Opinion · 2009 · 79 citations

Besifloxacin ophthalmic suspension 0.6% in patients with bacterial conjunctivitis: A multicenter, prospective, randomized, double-masked, vehicle-controlled, 5-day efficacy and safety study

Paul Karpecki, Michael DePaolis, Judy A. Hunter et al. · Clinical Therapeutics · 2009 · 77 citations

Ocular Disease, Ophthalmology, Safety Study +6

Ocular Pharmacokinetics of Besifloxacin Following Topical Administration to Rabbits, Monkeys, and Humans

Joel W. Proksch, Camille Granvil, R. Siou-Mermet et al. · Journal of Ocular Pharmacology and Therapeutics · 2009 · 66 citations

Maximum Besifloxacin Concentrations, Ocular Surface Physiology, Ocular Pharmacology +16

Effects of Loteprednol/Tobramycin Versus Dexamethasone/Tobramycin on Intraocular Pressure in Healthy Volunteers

Edward J. Holland, Jimmy D. Bartlett, Michael R. Paterno et al. · Cornea · 2008 · 65 citations